Minimal Vitrectomy Surgery for Epiretinal Membrane

Recruiting now · Not applicable

Conditions studied: Epiretinal Membrane, Macular Edema (ME), Nuclear Cataract

In brief

This multicenter randomized controlled trial evaluates Minimal Vitrectomy Surgery (MVS) versus conventional vitrectomy for idiopathic epiretinal membrane (ERM). The primary endpoints include visual acuity improvement and cataract progression after 12 months. MVS aims to minimize vitreous removal while ensuring complete membrane removal through adaptive limited vitrectomy.

Key facts

Study ID

NCT07019896

Run by

Peking Union Medical College Hospital

People needed

140

Starts

2024-12-01

Expected to finish

2026-11-30

Last updated by the study team

2025-06-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years.
• Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.
• Clear ocular media allowing adequate fundus imaging.
• Phakic eye.
• Ability and willingness to provide written informed consent.

You may not qualify if…

• Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).
• Systemic conditions preventing safe surgery or follow-up.
• History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.

Where it is running

• Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.